| Schedule of Basic and Diluted Earnings Per Share |
Shares used in the computation of the Company’s basic and diluted earnings per share are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (in thousands, except per share data) |
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
| |
|
2024 |
|
2023 |
|
2024 |
|
2023 |
| Numerator |
|
|
|
|
|
|
|
|
| Net increase (decrease) in net assets resulting from operations |
|
$ |
68,711 |
|
|
$ |
27,967 |
|
|
$ |
201,527 |
|
|
$ |
217,306 |
|
| Less: Total distributions declared |
|
(77,943) |
|
|
(72,534) |
|
|
(231,868) |
|
|
(204,687) |
|
| Total Earnings (loss), net of total distributions |
|
(9,232) |
|
|
(44,567) |
|
|
(30,341) |
|
|
12,619 |
|
|
|
|
|
|
|
|
|
|
| Earnings (loss), net of distributions attributable to common shares |
|
(9,232) |
|
|
(44,567) |
|
|
(30,341) |
|
|
12,486 |
|
| Add: Distributions declared attributable to common shares |
|
77,263 |
|
|
71,860 |
|
|
229,650 |
|
|
202,556 |
|
| Numerator for basic and diluted change in net assets per common share |
|
$ |
68,031 |
|
|
$ |
27,293 |
|
|
$ |
199,309 |
|
|
$ |
215,042 |
|
|
|
|
|
|
|
|
|
|
| Denominator |
|
|
|
|
|
|
|
|
| Basic weighted average common shares outstanding |
|
161,019 |
|
146,899 |
|
159,742 |
|
141,223 |
| Common shares issuable |
|
496 |
|
211 |
|
511 |
|
903 |
| Weighted average common shares outstanding assuming dilution |
|
161,515 |
|
147,110 |
|
160,253 |
|
142,126 |
|
|
|
|
|
|
|
|
|
| Change in net assets per common share: |
|
|
|
|
|
|
|
|
| Basic |
|
$ |
0.42 |
|
|
$ |
0.19 |
|
|
$ |
1.25 |
|
|
$ |
1.52 |
|
| Diluted |
|
$ |
0.42 |
|
|
$ |
0.19 |
|
|
$ |
1.24 |
|
|
$ |
1.51 |
|
|
| Schedule of Number of Anti-diluted Shares as Calculated Based on Weighted Average Closing Price of Common Stock |
The calculation of change in net assets resulting from operations per common share assuming dilution, excludes all anti-dilutive shares. For the three and nine months ended September 30, 2024, and 2023, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
| Anti-dilutive Securities |
|
2024 |
|
2023 |
|
2024 |
|
2023 |
| Unvested common stock options |
|
832 |
|
347 |
|
1,212 |
|
1,782 |
| Restricted stock units |
|
— |
|
— |
|
— |
|
5,810 |
| Unvested restricted stock awards |
|
152 |
|
395 |
|
398 |
|
40,034 |
|
|
|
|
|
|
|
|
|
|